All In Biotech

Drug Trial Radar · NCT07600021

A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis.

Last checked: Nov 20, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Oct 30, 2027

Study completion Dec 30, 2027

Sponsor

Sponsor type
Industry
First posted
May 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase II study. It Aims aims to evaluate the efficacy and safety of different doses of SYH2059 tablets compared with placebo in adult patients with IPF, observe the PK profile of SYH2059 tablets in adult IPF patients, and assess the population pharmacokinetic (PPK) profile, exposure-response (E-R) relationship, as well as the changing trends of blood biomarkers.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • SYH2059 TabletsDrug

    Take twice daily, about 12 hours apart, after meals, for 12 weeks.

  • PlaceboDrug

    Take twice daily, about 12 hours apart, after meals, for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in FVC from baseline (mL)Time frame: Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.